Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Robert T NaismithJerry S WolinskyAnnette WundesChristopher LaGankeDouglas L ArnoldDragana ObradovicMark S FreedmanMark GudesblattTjalf ZiemssenBoris KandinovIlda BidollariMaria Lopez-BresnahanNarinder NangiaDavid RezendesLili YangHailu ChenShifang LiuJerome HannaCatherine MillerRichard Leigh-Pemberton

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

Interim data from EVOLVE-MS-1 suggest DRF is a well-tolerated treatment with a favorable safety/efficacy profile for patients with RRMS.

Keyphrases

multiple sclerosis
white matter
electronic health record
big data
ms ms
systemic lupus erythematosus